Clarity Pharmaceuticals' prostate-cancer diagnostic could be...

Clarity Pharmaceuticals' prostate-cancer diagnostic could be highly differentiated from peers if its Phase 3 trial delivers on sensitivity and specificity, Bell Potter analysts say in a note. They tell clients that revenue timing remains highly uncertain and contingent on multiple factors, but that the Australia-listed clinical-stage radiopharmaceutical company looks to be well funded into FY 2025 and should be self-funding from FY 2026. Bell Potter cuts the stock's target price 7.1% to A$1.30 but maintains a speculative buy rating. ([email protected]; @StuartLCondie)